Researchers from Shandong University reported on the preclinical characterization of A3B3C-1, a multifunctional agent for the treatment of Alzheimer’s disease (AD), taking into account its complex nature. With multiple processes involved in its pathogenesis, the exploration of multi-target drugs may fit to address the combination of pathological factors in AD.
Scientists at Regeneron Pharmaceuticals Inc. have found a new way to permanently stop allergy through a combination of therapies that prevents the production of antibodies in secondary lymphoid organs and in bone marrow. The approach was tested in vivo in cynomolgus monkeys and in a mouse model.
Shanghai Meiyue Biotech Development Co. Ltd. has identified serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of fibrosis, cancer, autoimmune diseases, transplant rejection, cardiovascular, dermatological, endocrine, and inflammatory disorders, among others.
Hangzhou Healthytide Biotechnology Co. Ltd. has synthesized peptoids acting as integrin α5β1 (ITGA5; VLA-5) antagonists reported to be useful for the treatment of cancer and macular degeneration.
Dice Alpha Inc. has disclosed IL-17A inhibitors reported to be useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
The KCNC1 gene encodes the voltage-gated potassium channel subunit KV3.1, and variants in this gene have been previously linked to developmental and epileptic encephalopathy (DEE).
Neuexcell Therapeutics Inc. has announced that NXL-004, an investigational AAV gene therapy product being developed for the treatment of malignant glioma, has been awarded orphan drug designation by the FDA.
The Novo Nordisk Foundation is committing up to DKK1.8 billion (US$260 million) to establish a research and vaccine development initiative that aims to create new or improved vaccines for respiratory diseases, including tuberculosis (TB) and influenza.